



## EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

### MINUTES OF THE TEAMS MEETING 21<sup>st</sup> September 2022

#### PRESENT:

Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL ICB
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mr J Vaughan (JV)	Senior Medicines Commissioning Pharmacist NHS EL/BwD ICB
Ms Ana Batista (AB)	Medicines Information Pharmacist ELHT
Mr U Akram (UA)	Deputy Lead Pharmacist, LS CFT
Dr F Shah (FS)	GP/Consultant MFOP & Diabetes
Ms L Prince (LP)	Medicines Management Technician, EL ICB
Dr S Jackson (SJ)	GP Clinical Lead for Quality for Lancashire and South Cumbria ICS
Mr D Sebastian	Consultant Intensivist and Deputy DMD for SAS

#### IN ATTENDANCE:

Mr Michael Gill	Colorectal Surgeon, ELHT
Mr Alistair Gray	Clinical Pharmacist, ELHT

#### 2022/131: APOLOGIES:

Dr S Reilly	Consultant Community Paediatrician
Dr T Mackenzie	GP East Lancashire
Dr M Maher	Consultant Gynaecology & Sexual Health
Mrs H Robinson	Divisional Lead Pharmacist – MEC
Mr C Woods (CW)	Head of Contracting and Costing, Finance
Mr Neil Fletcher (NF)	Director of Pharmacy ELHT

#### 2022/132: DECLARATION OF INTEREST

None declared - relevant to agenda items

#### 2022/133: MINUTES OF JULY TEAMS MEETING:

Wording on page 3 item 117, mometasone to read '1<sup>st</sup> line alternative to fluticasone' Amendment acknowledged. July minutes will be updated.



### 2022/134: MATTERS ARISING:

**2021/101b:** ELMMB Membership – to remain on action matrix as a standing item for feedback. Currently awaiting appointment of new ICB Chief Pharmacist in November.

**2022/116b:** Stimulan Rapid Cure – Dr Baig to develop local guideline/pathway for use in ELHT, which will be submitted to Antimicrobial Committee for approval.

**Resolved:** item closed.

**2022/119d:** Melatonin prescriber information sheet – Comments circulated. Requires further clarity for traffic light status for prescribing in ADHD. LSCMMG document does not class neurodevelopment disorders and ADHD the same. Clinical evidence is poor, although used wisely by experienced clinicians. SR suggested maintaining the Traffic Light status as AMBER for ADHD to allow clinical practice to continue in ELHT. Regular reviews to be maintained by paediatric department.

**RESOLVED:** Maintain AMBER traffic light for use in paediatric ADHD patients. Adopt LSCMMG traffic light status for other indications

### 2022/135: New Product Request

a. **Vitamin E 100mg/2mL injection:** Unlicensed preparation for vitamin E deficiency [Alagille syndrome]. Use was prior approved for one patient only, where oral therapy was not improving vitamin E levels.

**Resolved:** use acknowledged by ELMMB. If more patient require this treatment, a new request will have to be submitted as this one was patient specific.

b. **EXPAREL (bupivacaine liposome injectable suspension)** requested by Mr Gill, colorectal surgeon for use with normal bupivacaine in TAP block in laparoscopic general surgery [minimal invasive resections]. It has a prolonged release of local anaesthetic [24 – 72 hours] meaning that the use of opiates post-operatively is minimized. The reduction in opiate use and the associated side effects will mean that there is no impact on length of stay in hospital, reducing cost and enhancing the recovery pathway for the patient. Exparel® is more expensive than normal bupivacaine, but this will be outweighed by the reduction in hospital stay and use of opiates.

**Resolved:** EXPAREL approved for use in minimal invasive colorectal surgery/resections subject to a review in June 2023 following an audit to evaluate its use further.

**Traffic Light: RED**

### 2022/136 Formulary Updates

a. **Captopril Liquid 5mg/5mL – deferred from meeting**

b. **Testosterone transdermal** – currently awaiting rag rating approval from LSCMMG where decision is pending as there is no Strategic Commissioning Committee. Its use will be for an unlicensed indication: supplementation for postmenopausal women with low sexual desire if HRT alone is not effective. Concerns were raised as there are no risk outcomes since the product has not been tested past 2 years. The available doses



can be titrated until optimal dose is achieved, with a blood test to determine the upper recommended limit and to keep the dosing in range. Also, if prescribed in private menopausal clinics and the GP is asked to take over prescribing, GPs need to be assured that the private provider has adhered to the Shared Care Guideline. Shared Care Guideline for unlicensed use of transdermal testosterone to be implemented as AMBER and to be reviewed when rag rating attributed at LSCMMG.

#### **Traffic Light: AMBER Shared Care**

- c. **Baricitinib** – recommended within national guidelines for the treatment of adults and children [aged 2 years and over], hospitalised with Covid-19 in accordance with set criteria. It is funded by NHSE via blueteq. **Traffic Light: RED**
- d. **Methenamine Hippurate**- This product is already on formulary. Request to be prescribed by brand: Hiprex® **Traffic Light: GREEN**
- e. **Dexcom one** – to be included in formulary in line with National criteria for accessing Flash Glucose Monitors **Traffic Light: AMBER**
- f. **Liothyronine** – for information. Agreed as RED Traffic light for all indications **Traffic Light: RED**
- g. **Additional item – Biotin and Alpha tocopherol supplements** for metabolic disorders are currently AMBER traffic light. It was agreed that prescribing these supplements in primary care is very expensive. They are also not licensed for this indication and there is a huge variation in the charges incurred. The items can be readily purchased over the counter quite cheaply. Agreed to look into the numbers [to include other supplements] and bring to future meeting for discussion.

**Action:** Formulary to be updated accordingly. LR to look into the numbers of patient receiving biotin and alpha tocopherol supplements and bring back to re-discussed in October.

#### **2022/137 LSCMMG Consultations – August 2022 [deadline was 1<sup>st</sup> September]**

- a. Atrial Fibrillation pathway
- b. Oral nutritional supplementation guideline
- c. Ryaltris re-consultation
- d. Mexiletine for ventricular arrhythmias:
- e. Infliximab s/c – gastroenterology
- f. Vedolizumab s/c – gastroenterology

It was noted that item d. Mexiletine was approved as RED traffic light by LSCMMG for 12 months whilst a shared care guideline is developed. ELMMB has previously approved as AMBER. It was agreed that the local decision will remain.

**Resolved:** Items acknowledged by ELMMB

#### **2022/138 LSCMMG Consultations – September 2022**

- a. Softacort eye drops new medicines Ophthalmology Consultants have replied to the consultation directly. LR to submit feedback from SJ to LSCMMG.



- b. Efmody new medicines assessment – Originally requested by ELMMB, agreed with proposal. AB to submit feedback on behalf of ELMMB

### 2022/139 LSCMMG Recommendations – July 2022

- a. Primary care PPI review guideline
- b. Varenicline position statement – updated
- c. Asthma desktop guideline
- d. Amiodarone shared care guideline – updated
- e. Lipid pathway guideline

(None for **August** as no meeting took place)

**Resolved:** items acknowledged

**For Action:** updated items will be replaced on ELMMB

### 2022/140 Strategic Commissioning Committee (SCC) Decisions – July 2022

None (Group no longer active, awaiting update)

### 2022/141 Other Items

**Colecaliferol 3000units/mL liquid dosing** - As part of the preparation to go live for the electronic prescribing and medicines administration (ePMA) part of Cerner's Millennium e-patient record (ePR) we have been creating Order Sentences to make it easy to prescribe medicines with the right dose, form, frequency instructions. As it is not possible to add a dose of 6.6mL to the system, AG requested the dose to be agreed as 7mL (21,000 units) for patient using the liquid.

**Resolved:** Agreed

### 2022/142 Other Items

**5 MINUTE FACTS - Paracetamol Dosing** - Advice to healthcare professionals – request to use in Primary Care.

This is an ELHT document that is awaiting approval. Final copy to be circulated.

**Resolved:** Acknowledged for use in primary when final version available

### 2022/143 Other Items

**Your asthma plan / Your MART asthma plan**

LR requested feedback on the plans for the workplan to be updated accordingly.

**Resolved:** Plans acknowledged for use following feedback/updates.

### 2022/144 Other Items

**Ketone testing and sick day guidance** – request to adopt the guidance submitted to ELMMB. It provides information on ketone testing and responsibility for primary and secondary care clinicians to provide ketone testing

**Resolved:** Acknowledged for use by ELMMB



**2022/145 NICE Guidance – July and August 2022**

To be included on October's agenda

**2022/146 NICE Recommendations – July and August 2022**

Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs as an option by NICE. Approved in line with NICE TA803  
ICS Commissioned. Blueteq required. **Traffic Light: RED**

Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides as an option by NICE. Approved in line with NICE TA805  
ICS Commissioned **Traffic Light: GREEN**  
**[provisionally]**

Belimumab for treating lupus nephritis (terminated appraisal) is not recommended as an option as per NICE TA806 **Traffic Light: BLACK**

Roxadustat for treating symptomatic anaemia in chronic kidney disease as an option by NICE. Approved in line with NICE TA807  
ICS Commissioned. Blueteq required. **Traffic Light: RED**

Fenfluramine for treating seizures associated with Dravet syndrome as an option by NICE. Approved in line with NICE TA808  
NHSE Commissioned **Traffic Light: RED**

Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease as an option by NICE. Approved in line with NICE TA809  
NHSE Commissioned **Traffic Light: RED**

Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence as an option by NICE. Approved in line with NICE TA810  
NHSE Commissioned **Traffic Light: RED**

Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) is not recommended as an option as per NICE TA811 **Traffic Light: BLACK**

Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer is not recommended as an option by NICE TA812. **Traffic Light: BLACK**

Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors as an option by NICE. Approved in line with NICE TA813  
NHSE Commissioned **Traffic Light: RED**

Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis as an option by NICE. Approved in line with NICE TA814  
ICS Commissioned. Blueteq required. **Traffic Light: RED**



Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs as an option by NICE. Approved in line with NICE TA815  
ICS Commissioned. Blueteq required. **Traffic Light: RED**

Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer as an option by NICE. Approved in line with NICE TA816  
NHSE Commissioned **Traffic Light: RED**

Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence as an option by NICE. Approved in line with NICE TA817.  
NHSE Commissioned **Traffic Light: RED**

Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma as an option by NICE. Approved in line with NICE TA818  
NHSE Commissioned **Traffic Light: RED**

Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies as an option by NICE. Approved in line with NICE TA819.  
NHSE Commissioned **Traffic Light: RED**

Brolucizumab for treating diabetic macular oedema as an option by NICE. Approved in line with NICE TA820  
ICS Commissioned. Blueteq required. **Traffic Light: RED**

Avalglucosidase alfa for treating Pompe disease as an option by NICE. Approved in line with NICE TA821  
NHSE Commissioned **Traffic Light: RED**

**Resolved:** Items acknowledged by ELMMB

#### **2022/147 NICE Highly Specialised Technologies – July and August 2022**

**HST21 Setmelanotide** for treating obesity caused by LEPR or POMC deficiency  
**Resolved:** Item acknowledged by ELMMB

#### **2022/148 EAMS (Early access to medicines scheme) – July and August 2022**

**Voxelotor** in the treatment of sickle cell disease  
**Resolved:** Item acknowledged by ELMMB

#### **Standing Items:**

**2022/149 For Action/Information:** Lancashire & South Cumbria Medicines Management Group (LSCMMG)

DRAFT LSCMMG minutes 14.07.2022  
**Resolved:** Minutes acknowledged.

**2022/150 For Action/Information:** Lancashire & South Cumbria FT Drugs and Therapeutics Committee



- a. Minutes from the Drugs and Therapeutics Committee Meeting Minutes 21st July 2022 10.8
  - b. Drugs and Therapeutics Committee Meeting Action Tracker updated July 22 10.8
- Next meeting: Thursday 22<sup>nd</sup> September 2022  
**Resolved:** Minutes acknowledged.

**2022/151 For Action/Information: Antimicrobial Stewardship Committee (ASC)**

- a. ASC - minutes 17th May 2022
  - b. ASC - action matrix 17th May 22
- (No meeting took place in June and July, August minutes not yet available)

**Resolved:** acknowledged by ELMMB.

**DATE OF NEXT MEETING – Wednesday 19th October 2022 12.30pm via ‘Microsoft Teams’**

**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 20<sup>th</sup> July 2022**

<b>MINUTE</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
---------------	--------------------	---------------	-------------



NUMBER			
2021/101b	<b>ELMMB Membership</b> A review will be required to decide how ELMMB links with the ICS and ICB in the future and the policy for introduction of new drugs will required review as a result of that.	LR/VG	Oct 22
2022/136 g	<b>Biotin and Alpha tocopherol supplements</b> LR to look into the numbers of patient receiving biotin and alpha tocopherol supplements and bring back to re-discussed in October.	LR	Oct 22
2022/145	<b>NICE Guidance – July and August 2022</b> To be added to October's agenda	AB	Oct 22